Ignite Creation Date:
2024-05-05 @ 9:37 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00927134
Status:
COMPLETED
Last Update Posted:
2011-09-27
First Post:
2009-06-22
Brief Title:
Gene Therapy for X-linked Chronic Granulomatous Disease CGD in Children
Sponsor:
University of Zurich
Organization:
University of Zurich
Study Overview
Official Title:
Phase III Gene Therapy Study for X-linked Chronic Granulomatous Disease in Children
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
XCGDinChildren
Brief Summary:
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34 cells of the peripheral blood of chemotherapy conditioned busulphan children with chronic granulomatous disease CGD Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None